Invesaro

Stocks Technology WEWA

OTC · Technology

Wewards, Inc. (WEWA)

Wewards, Inc. reported revenue of $0 in fiscal 2026. It posted a net loss of $497.5K. At May 31, 2026 it held $0 in cash. Its latest periodic report to the SEC is the annual report (10-K) filed on September 14, 2026.

Watch WEWA in 60 seconds
Price
$2.00
0.00% on the day · September 25, 2026
52-week range $2.00 to $2.11
Market cap
$215M
Revenue (FY2026)
$0

What Wewards, Inc. does

Wewards, Inc. is registered with the SEC under industry code SIC 7370 (Services-Computer Programming, Data Processing, Etc.). Its shares trade on OTC under the ticker WEWA.

Revenue and profit by year

Revenue
FY20: $4.2K $4.2K FY20FY21: $83.5K $83.5K FY21FY23: $0 $0 FY23FY24: $0 $0 FY24FY25: $0 $0 FY25FY26: $0 $0 FY26
Net income
FY19: -$2.4M -$2.4M FY19FY20: -$897.4K -$897.4K FY20FY21: -$1.5M -$1.5M FY21FY22: -$2.4M -$2.4M FY22FY23: -$760.7K -$760.7K FY23FY24: -$651.7K -$651.7K FY24FY25: -$596.1K -$596.1K FY25FY26: -$497.5K -$497.5K FY26

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2026$0-$76.7K-$497.5K$0.00n/a
2025$0-$90.7K-$596.1K-$0.01n/a
2024$0-$145.8K-$651.7K-$0.01n/a
2023$0-$245.3K-$760.7K-$0.01n/a
2022n/a-$1.9M-$2.4M-$0.02n/a
2021$83.5K-$1M-$1.5M-$0.01n/a

Full financial statements: income, balance sheet and cash flow

Next report expected around October 13, 2026.

Estimated from its filing rhythm: 52 weeks after its report of October 14, 2025. Not a date the company has announced. See the report calendar

Latest SEC filings

What Wewards, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 14, 2026
    Annual report 10-K · period to May 31, 2026Diluted EPS $0.00 versus -$0.01.
  2. August 31, 2026
  3. March 17, 2026
    Quarterly report 10-Q · period to February 28, 2026Diluted EPS $0.00 versus $0.00.
  4. January 20, 2026
    Quarterly report 10-Q · period to November 30, 2025Diluted EPS $0.00 versus $0.00.
  5. January 15, 2026
  6. October 14, 2025
    Quarterly report 10-Q · period to August 31, 2025Diluted EPS $0.00 versus $0.00.
  7. August 20, 2025
    Annual report 10-K · period to May 31, 2025Diluted EPS -$0.01 versus -$0.01.
  8. April 16, 2025
    Quarterly report 10-Q · period to February 28, 2025Diluted EPS was $0.00.
  9. April 15, 2025
  10. March 28, 2025
    Annual report (amended) 10-K/A · period to May 31, 2024Diluted EPS -$0.01 versus -$0.01.

Recent insider filings (Forms 3, 4 and 144): 3, the latest on April 29, 2019. Insider transactions on SEC

All filings on SEC EDGAR

Questions about WEWA

What does Wewards, Inc. do?

Wewards, Inc. is registered with the SEC under industry code SIC 7370 (Services-Computer Programming, Data Processing, Etc.). Its shares trade on OTC under the ticker WEWA.

Is Wewards, Inc. profitable?

No. In fiscal 2026 it reported a net loss of $497.5K.

How much revenue does Wewards, Inc. make?

In fiscal 2026 Wewards, Inc. reported revenue of $0.

When did Wewards, Inc. last report?

Its most recent periodic report is the annual report (10-K) filed on September 14, 2026. It covers the period to May 31, 2026.

Similar companies

Compare WEWA with

Compare WEWA with any company

Follow WEWA

Get an email when Wewards, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow WEWA: get an email when it files

Where the numbers come from

Financial figures are the values Wewards, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.